Literature DB >> 19010140

Treatment with N-acetylcysteine in stable renal transplantation.

M C Ruiz Fuentes1, J M Moreno Ayuso, N Ruiz Fuentes, J F Vargas Palomares, C Asensio Peinado, A Osuna Ortega.   

Abstract

The primary cause of morbidity and mortality in renal transplantation is cardiovascular disease. Increased oxidative stress implies a greater degree of atherogenesis in these patients. N-acetylcysteine (NAC) which has a thiol group that is the source of l-cysteine and reduced glutathione, acts against atherosclerosis via a decrease in apoptosis, vasoconstriction, and endothelial dysfunction. Experimental models have examined the antioxidant effects of NAC during and after ischemia-reperfusion, but few studies have shown an effect in renal transplantation in human beings. In 8 months, we studied the effect of NAC treatment on oxidative stress, lipids, and renal function in 25 patients with stable renal function and no diabetes after transplantation. Data were collected on oxidative parameters: malondialdehyde, glutathione peroxidase, catalase, superoxide dismutase, glutathione reductase, lipid profile, and renal function (creatinine concentration, Cockroft-Gault formula, and Modified Diet in Renal Disease study). There were no significant differences in oxidative profile before and after treatment with NAC. The mean serum high-density lipoprotein cholesterol fraction increased after treatment and showed a significant positive correlation with glutathione peroxidase (r = 0.495). Serum creatinine concentration decreased, and Cockroft-Gault and Modified Diet in Renal Disease study estimates of renal function increased in the treatment period. In conclusion, NAC treatment in patients with stable renal function after transplantation increased high-density lipoprotein cholesterol and antioxidant molecules in relation to glutathione peroxidase, with a positive influence on renal function.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19010140     DOI: 10.1016/j.transproceed.2008.08.109

Source DB:  PubMed          Journal:  Transplant Proc        ISSN: 0041-1345            Impact factor:   1.066


  4 in total

1.  N-acetyl-cysteine is associated to renal function improvement in patients with nephropathic cystinosis.

Authors:  Luciana Pache de Faria Guimaraes; Antonio Carlos Seguro; Maria Heloisa Mazzola Shimizu; Letícia Aparecida Lopes Neri; Nairo Massakasu Sumita; Ana Carolina de Bragança; Rildo Aparecido Volpini; Talita Rojas Cunha Sanches; Fernanda Andrade Macaferri da Fonseca; Carlos Alberto Moreira Filho; Maria Helena Vaisbich
Journal:  Pediatr Nephrol       Date:  2013-12-11       Impact factor: 3.714

2.  Outcomes of Endovascular Aortic Aneurysm Repair in Kidney Transplant Recipients: Results From a National Quality Initiative.

Authors:  I C Bostock; D S Zarkowsky; C W Hicks; D H Stone; M H Eslami; M B Malas; P P Goodney
Journal:  Am J Transplant       Date:  2016-03-31       Impact factor: 8.086

3.  PARP inhibition attenuates acute kidney allograft rejection by suppressing cell death pathways and activating PI-3K-Akt cascade.

Authors:  Karoly Kalmar-Nagy; Peter Degrell; Aliz Szabo; Katalin Sumegi; Istvan Wittmann; Ferenc Gallyas; Balazs Sumegi
Journal:  PLoS One       Date:  2013-12-03       Impact factor: 3.240

4.  Study of The Effects of N-Acetylcysteine on Oxidative Stress Status of Patients on Maintenance-Hemodialysis Undergoing Cadaveric Kidney Transplantation.

Authors:  Atieh Modarresi; Shadi Ziaie; Jamshid Salamzadeh; Zahra Sahraei; Mohsen Nafar; Yunes Panahi; Mahmoud Parvin; Behzad Einollahi
Journal:  Iran J Pharm Res       Date:  2017       Impact factor: 1.696

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.